Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15337408 | 0.83 | KDM4E (0.39) | ALDH1A1KMT2ATSHRNOTUMHPGD | |
| SCHEMBL10199133 | 0.80 | NOTUM (0.33) | ALDH1A1NOTUM | |
| SCHEMBL18066859 | 0.80 | ALDH1A1 (0.40) | ALDH1A1NPSR1HPGDKDM4EUSP2 | |
| SCHEMBL15783485 | 0.80 | ALDH1A1 (0.33) | ALDH1A1KMT2ATSHRNOTUMHPGD | |
| SCHEMBL18994963 | 0.80 | NOTUM (0.36) | ALDH1A1KMT2ATSHRNOTUMHPGD | |
| SCHEMBL433874 | 0.78 | ALDH1A1 (0.43) | ALDH1A1NPSR1HPGDKDM4EPOLB | |
| SCHEMBL431148 | 0.77 | ALDH1A1 (0.43) | ALDH1A1KMT2ATSHRNPSR1NOTUM | |
| SCHEMBL15790774 | 0.77 | POLB (0.40) | ALDH1A1KMT2ATSHRNPSR1NOTUM | |
| SCHEMBL1740735 | 0.77 | ALDH1A1 (0.55) | ALDH1A1KMT2ATSHRNPSR1NOTUM | |
| SCHEMBL19836154 | 0.76 | ALDH1A1 (0.35) | ALDH1A1KMT2ATSHRNPSR1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10792282-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| EP-2595982-B1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2018-06-13 | — | — | EP | disclosed |
| EP-2595982-B1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2018-06-13 | — | — | EP | disclosed |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2018-02-01 | — | — | US | disclosed |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2018-02-01 | — | — | US | disclosed |
| US-20170360786-A1 | Protein Kinase C Inhibitors and Uses Thereof | RIGEL PHARMACEUTICALS, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170360786-A1 | Protein Kinase C Inhibitors and Uses Thereof | RIGEL PHARMACEUTICALS, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9682976-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-8710223-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710223-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710223-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| WO-2013152198-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-10 | — | — | WO | disclosed |
| EP-2595982-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | Rigel Pharmaceuticals, Inc. (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20120022092-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2012-01-26 | — | — | US | disclosed |
| US-20120022092-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2012-01-26 | — | — | US | disclosed |
| US-20120022092-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2012-01-26 | — | — | US | disclosed |
| WO-2012012619-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012012619-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360786-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | ALDH1A1 4361/4885KMT2A 3505/4885TSHR 3710/4885 |
| US-20120022092-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | ALDH1A1 4361/4885KMT2A 3505/4885TSHR 3710/4885 |
| US-10792282-B2 | Protein kinase C inhibitors and uses thereof | PRKCH, PRKCA, PRKCB | ALDH1A1 4361/4885KMT2A 3505/4885TSHR 3710/4885 |
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | PRKCH, PRKCA, PRKCB | ALDH1A1 4361/4885KMT2A 3505/4885TSHR 3710/4885 |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | ALDH1A1 4361/4885KMT2A 3505/4885TSHR 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.